Adverse Reactions to Allergy Shots: Full Clinical Classification System

The WAO (World Allergy Organization) systemic reaction grading system was published by Cox, Larenas-Linnemann, Lockey, and Passalacqua in JACI 2010 (125:569-574) and is endorsed by AAAAI, ACAAI, SLAAI, and APAAACI as the international standard for classifying SCIT adverse events. The system grades by the most severe organ system involved. Grade 1 (mild): single organ system — cutaneous, upper-respiratory, or conjunctival only. Grade 2 (moderate): more than one organ system, or lower-airway involvement responding to bronchodilator, or gastrointestinal. Grade 3 (severe): lower-airway bronchospasm with greater than 40% PEF/FEV1 drop not responding to bronchodilator, or laryngeal edema. Grade 4 (anaphylaxis): respiratory failure with or without loss of consciousness, or hypotension with or without loss of consciousness. Grade 5 (fatal). A 2024 update by Turner et al. aligned grading with CoFAR v3.0 criteria and further specified Grade 4 respiratory criteria.

Adverse reactions to allergy shots are classified by onset timing as immediate (beginning within 30 minutes of injection) or delayed (beginning after 30 minutes). Immediate reactions are typically IgE-mediated: allergen cross-links IgE antibodies on mast cell surfaces, triggering rapid degranulation and histamine release within minutes. Delayed reactions involve T-cell-mediated late-phase immune responses, with onset at 6-24 hours for local delayed reactions and potentially longer for certain systemic presentations. Epstein 2019 confirmed that approximately 85% of systemic reactions begin within 30 minutes and 15% are delayed-onset. Larenas-Linnemann 2017 (JACI Pract) reported a higher 52.8% delayed rate in a single-center 10-year series — a striking outlier suggesting practice-level variation in delayed reaction detection. Because most immediate reactions begin early, at-home programs like Curex confirm a prescribed epinephrine auto-injector is on hand and supervise the first injection and every dose change live over Zoom.

In the United States, adverse reactions to allergen extracts used for immunotherapy fall under FDA MedWatch voluntary reporting (Form 3500 for healthcare providers, Form 3500B for patients). Allergen extracts are classified as biological products regulated by the FDA Center for Biologics Evaluation and Research (CBER). Mandatory expedited reporting (15-day safety reports) applies to unexpected serious adverse events for licensed biological products. Voluntary reporting is encouraged for all serious adverse events, including severe anaphylaxis and fatalities. The AAAAI/ACAAI National Surveillance Study series, which is the largest SCIT safety dataset, operates through voluntary practice participation rather than mandatory regulatory reporting — which means its capture rate of adverse events depends on practice-level documentation and voluntary data submission. VAERS (Vaccine Adverse Event Reporting System) is not applicable to allergen immunotherapy extracts, which are not vaccines.

Causality assessment for SCIT adverse reactions evaluates the probability that an observed adverse event was caused by the allergen injection rather than by coincident illness, medication effect, or spontaneous disease. The three primary criteria are: temporal relationship (onset within the expected reaction window, typically 30 minutes for immediate reactions), de-challenge response (reaction resolves with appropriate treatment), and re-challenge pattern (recurrence on subsequent injection or dose). Exclusion of alternative causes — concurrent infection, food allergen exposure, exercise-induced anaphylaxis, drug reaction — is part of the causality evaluation. In severe reactions, the reaction curve (rapid onset and multi-system involvement typical of IgE-mediated anaphylaxis) versus alternative patterns helps distinguish SCIT-caused from coincident events. Adequate documentation in the patient record — time of injection, time of reaction onset, specific symptoms with grade assessment, treatments administered, and outcome — enables meaningful causality analysis.

The 2011 AAAAI/ACAAI Practice Parameter Third Update provides dosing guidance following adverse reactions, though explicitly notes no single protocol has been universally validated. Common conventions are: after Grade 1 systemic reaction, reduce to approximately 50% of the reaction-causing dose or step back one dose and advance conservatively. After Grade 2, reduce to approximately 10% of the reaction-causing dose — equivalent to 2-3 dilutions back in the vial series — and reassess the build-up schedule. After Grade 3, reduce to 1% of the reaction-causing dose (10-fold dilution) and consider strongly whether continuation of SCIT is medically justified given recurrence risk. For new vial transitions, the standard recommendation is 50% dose reduction regardless of prior reaction history. The Wilford Hall protocol — validated retrospectively across 12,895 injections (Coop 2010) — provides a structured dose-reduction algorithm. All post-reaction dose adjustments should be explicitly documented with the triggering grade, the adjusted starting dose, and the rationale.

Grade distribution data from the Bernstein 2010 Year 1 surveillance study (8.1 million visits, 8,502 systemic reactions) establishes the reference distribution: Grade 1 accounts for 74% of all systemic reactions, Grade 2 for 23%, and Grade 3 for approximately 3%. Grade 4 anaphylaxis accounts for a small fraction — approximately 1 per 160,000 injection visits. Combining Grades 3 and 4 as 'severe,' approximately 3-4% of systemic reactions reach this threshold. The 19% severe classification cited in some indirect comparisons reflects a different severity threshold definition — summarizing published trial data rather than the population-level surveillance database. The surveillance database's 3% severe rate represents the more broadly applicable population estimate. In absolute terms, severe systemic reactions (Grades 3-4) occur at approximately 3-4 per million injection visits.